Bassel El-Rayes

Has grant

Deputy Director

University of California, San Diego
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Open

Targeting Cancer Associated Fibroblasts in Colorectal Cancer

Open Date: 2024-08-01

Close Date: 2028-08-01

Grant: Open

ProAgio in Pancreatic Cancer

Open Date: 2024-07-01

Close Date: 2029-06-30

Grant: Open

DCE-MRI guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer

Open Date: 2024-04-01

Close Date: 2029-03-31

Grant: Close

Modulation of the human pancreatic microenvironment by combined cytokine and immune checkpoint blockade

Open Date: 2022-01-01

Close Date: 2025-12-31

Grant: Close

A novel therapy for pancreatic neuroendocrine tumors

Open Date: 2020-04-01

Close Date: 2026-03-31

Articles (21)

143 Background: Colorectal liver metastasis (LM) presents a therapeutic challenge in tailoring optimal treatment for patients. HAIP delivers high-dose regional chemotherapy to the liver, maximizing local drug exposure while minimizing systemic toxicity. Real-world impact of HAIP on patient tolerance, and survival outcomes is limited. We report HAIP outcomes in a contemporary cohort. Methods: We performed a retrospective review of CRC patients with LM who received HAIP at UAB between (2021-2025). Demographics, tumor characteristics, and liver function tests (LFTs) were collected, alongside treatment details including dose reductions, treatment breaks, and disease response. Chi-square and Fisher-exact tests were used to evaluate differences between categorical variables. Median progression free survival (mPFS) was estimated via Kaplan-Meier estimates. Results: Among 53 patients, (mean age 54 at diagnosis; 60.4% male; 67.9% Caucasian), 75.5% presented with left sided CRC and (67.9%) had bilobar LM ranging between 1 to 10 lesions. Prior HAIP placement, patients were on chemotherapy for median of 9.4 months. Around 71.6% were on FOLFOX. KRAS (45.2%) and BRAF (30.1%) were the most common mutations detected. 64.1% of patients experienced FUDR dose reductions, while (60.3%) had HAIP treatment interruptions due to LFT changes. These modifications showed no association with disease progression (p = 0.340). 52.8% discontinued HAIP due to LFTs fluctuations, disease progression or infection. Worsening LFTs were not linked to radiologic response, recurrence or disease progression (p = 0.542, 0.844, 0.307, respectively). Stable disease at 6 months was observed in 51%, and curative liver resection was achieved in 17%. After >6 months of HAIP, 83% remained alive. Median progression-free survival (mPFS) was 13 months (95% CI 8.8-17.9). Highest risk of progression was between 10–20 months after HAIP treatment initiation. 20% had extra-hepatic progression mostly to the lung or bones, and this was significantly associated with BRAF, KRAS (p < 0.001). Conclusions: In this real-world cohort, HAIP was associated with prolonged PFS, despite dose modifications in many. Most progression occurred within the first 20 months. Appropriate patient selection for HAIP based on disease biology is vital. It can offer meaningful survival benefit in selected patients, warranting further prospective comparative studies.

Year:

2026

Year:

2026

TPS613 Background: Enhancer of zeste homolog 2 (EZH2) is overexpressed in HCC and correlates with poor prognosis. Preclinical studies demonstrated that EZH2 regulates immune evasion and EZH2 inhibition enhances NK cell–mediated anti-tumor activity in HCC cell lines. EZH2 inhibition combined with anti-PD-L1 blockade leads to increased CD8⁺ T cell trafficking and synergistic anti-tumor effect in HCC murine models. Valemetostat tosylate (DS-3201b) is a dual EZH1/EZH2 inhibitor with potential to restore immune sensitivity and synergize with immune checkpoint inhibitor-based therapy in HCC. Based on this preclinical rationale, we designed a phase Ib/II study to determine the recommended phase II dose (RP2D), evaluate the safety, toxicity profile, preliminary anti-tumor activity, and correlative outcomes of valemetostat, atezolizumab and bevacizumab in patients with treatment-naive advanced HCC. Methods: The phase Ib trial design is a standard 3+3 dose-escalation study. Primary endpoints of phase Ib are RP2D, safety and tolerability. Primary endpoint of phase II (dose expansion) cohort is to estimate objective response rate by RECIST version 1.1 per investigator assessment. Secondary endpoints of the study are overall survival, progression free survival, disease control rate, duration of response, pharmacokinetic profile. Correlative endpoint is to explore immunological biomarkers of treatment response. A Simon’s two stage design will be used for phase II portion of the study (H0: ORR=27.3%; H1: ORR=48%; Type I error=0.1; power=80%). After RP2D is established, 10 patients will be enrolled in the first stage of dose expansion phase (phase II). If three or more objective responses are observed, 17 additional patients will be enrolled in the second stage of phase II (27 total patients). Eleven or more objective responders in 27 patients would be required to be considered positive study. Valemetostat is administered orally (PO) daily in three dose levels of 100 (DL-1, only if ≥2 DLTs observed at DL1), 150 (DL1), 200 (DL2) mg with standard dose of atezolizumab 1200 mg IV on day 1, and bevacizumab 15 mg/kg IV on day 1 of each cycle, in 21-day cycles. Eligible patients must have advanced HCC diagnosis confirmed by histology/cytology or clinically by American Association of Liver Diseases (AASLD) criteria for cirrhotic patients, age ≥18 years, ECOG PS 0-1, Child Pugh Class A, measurable disease per RECIST v1.1, adequate organ function, no prior systemic therapy for advanced HCC. Restaging scans will be performed every 9 weeks. Serial peripheral blood samples and optional paired biopsies will be collected for correlative research. This study was activated in July 2025. Clinical trial information: NCT06294548 .

Year:

2026

Aims Accurate determination of tumour size is critical for pT staging in pancreatic ductal adenocarcinoma (PDAC), yet gross measurement alone often underestimates the true tumour extent because of the tumour's ill‐defined and infiltrative nature. This study aimed to evaluate the diagnostic and prognostic value of incorporating microscopic rectification into tumour size assessment in PDAC. Methods and results A total of 342 therapy‐naïve pancreatoduodenectomies were analysed using a grossing protocol that includes separate sampling of anterior and posterior soft tissues via the ‘orange‐peeling’ technique to retrieve lymph nodes and document soft tissue involvement. Peripancreatic soft tissue involvement was present in 91% of cases, and isolated microscopic foci distant from the main mass in 48%. Of the 266 tumours grossly classified as pT1/T2 (≤4 cm), 39 (14%) showed carcinoma in both anterior and posterior soft tissues, and were reclassified as pT3. This subset showed significantly worse survival ( P = 0.04) and higher nodal positivity (87% versus 69%, P = 0.02) than the remaining pT2 cases, comparable to conventional pT3 tumours (86%, P = 0.77). Multivariable Cox regression adjusted for age, sex, nodal status, margin, and lymphovascular/perineural invasion confirmed the survival disadvantage of this subgroup. Reclassification yielded a more balanced distribution of T categories (pT2 66% → 52%, pT3 22% → 34%) and modestly improved prognostic discrimination (C‐index: 0.592 versus 0.574). Conclusions This study elucidates that PDAC frequently extends beyond the visible mass (‘horses out of the barn’ phenomenon); peripancreatic soft tissue involvement is common, and gross size often underestimates the true tumour extent, making microscopic correction crucial. Approximately one in six pT1/T2 tumours (≤4 cm) shows carcinoma in both anterior and posterior soft tissues and behave like pT3 in outcomes and nodal status. Therefore, gross‐micro rectification is essential to avoid understaging, particularly for T2 tumours. The orange‐peeling protocol should classify tumours with foci in both anterior and posterior soft tissues as pT3, while other approaches may employ mapping techniques to enable microscopic reconstruction and biologically accurate staging.

Year:

2026

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive tumor type with poor patient outcomes. Most patients present with metastatic disease, which generally has reduced immune infiltration compared to primary tumors. Further work to elucidate the specific cellular features of metastatic PDAC is needed to guide the development of future immunotherapy strategies. Here, we investigated the hypothesis that PDAC tumors harbor distinct immunologic and stromal features depending on their anatomical site. Multiplex immunohistochemistry (mIHC), spatial analysis, and single-cell mass cytometry (CyTOF) uncovered dominant immune and stromal cell populations in tumors derived from 27 primary and 26 liver metastases. Metastatic liver tumors from PDAC patients contained reduced T cell infiltration, fibroblast populations, and collagen accumulation than primary lesions, while CD68+ cells, often co-expressing CCR2, were more abundant. Spatial analyses revealed distinct immune cell communities in primary and metastatic PDAC, whereby CK19+ cells clustered differentially with α-SMA+, CD3+, and CD68+ cells, depending on the tumor site. When comparing tumor-associated regions, the proportion of peritumoral CK19- cells remained consistent, but their composition varied by disease site. CD8+ T cells were significantly less frequent in metastatic tumors, while both CD4+ and CD8+ T cells present in primary tumors expressed more transcription factors (TFs) associated with suppressive properties, including FoxP3 and RORγt. CyTOF revealed that T cells co-expressed multiple inhibitory checkpoint receptors, most notably LAG-3 and PD-1. This report reveals that primary and metastatic tumors from PDAC patients harbor vastly distinct immunologic and stromal features at the protein level.

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Collaborators (18)

Garima Gupta

Assistant Professor of Medicine

University of Alabama, Tuscaloosa

UNITED STATES
View details

Misako Nagasaka

University of California Irvine School of Medicine

UNITED STATES
View details

Olatunji B. Alese

Emory University

UNITED STATES
View details

Emil Lou

University of Minnesota

UNITED STATES
View details

SANJAY GOEL

Rutgers University

UNITED STATES
View details

Bassel Nazha

Emory University School of Medicine

UNITED STATES
View details

MEHMET AKCE

Associate Professor

The University of Alabama

UNITED STATES
View details

Julien Edeline

PU-PH - Full Professor

Université de Rennes 1 Faculté de Médecine

FRANCE
View details

Debashis Sarker

King’s College London

UNITED KINGDOM
View details

Heloisa Soares

Associate Professor

Huntsman Cancer Institute

UNITED STATES
View details

Shishir K. Maithel

Professor of Surgery

Northwestern Medicine

UNITED STATES
View details

Petr Hausner

Professor of Medicine

University of Maryland Medical Center

UNITED STATES
View details

Ganji Purnachandra Nagaraju

The University of Alabama

UNITED STATES
View details

Tim Meyer

University College London

UNITED KINGDOM
View details

Mohd Khushman

Professor

Washington University in St. Louis

UNITED STATES
View details

Donald Buchsbaum

The University of Alabama

UNITED STATES
View details

Boris Pasche

Chair

Karmanos Cancer Institute

UNITED STATES
View details

Seema Kumari

Faculty

Medical College of Wisconsin

UNITED STATES
View details